California’s SB 535 Provides Better Access to Biomarker Testing
California’s SB 535 prohibits insurers that already cover biomarker testing from requiring prior authorization for patients with advanced stage cancer.
Read More
Search Results for: lung cancer
OneOncology: NGS Testing Is Backbone of Personalized Treatments
OneOncology and Genentech presented data at a symposium that examined genomic profiling and biomarker testing patterns in community oncology centers.
Read More
What’s Next for Liquid Biopsy Tests?
Foresight Diagnostics CEO and CSO Jake Chabon gives an overview of what’s next for liquid biopsy testing, and how it will impact the continuum of care.
Read More
Thermo Fisher’s Oncomine Dx Receives FDA Premarket Approval
The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic.
Read More
Biodesix Announces Liquid Biopsy NGS Test with 72-Hour Turnaround
The study showed that the rapid liquid biopsy NGS test was able to accurately detect actionable genomic alterations in patients with NSCLC with a turnaround time of only 72 hours.
Read More